biosurfit, a rapidly-growing company focused on the Point of Care medical diagnostic market, is pleased to announce that, as part of a €6.0 million consortium project (Grant n° 601851) for the development of Point of Care Hepatitis C assays, has been awarded funding of €1.4 million over a three year period by the European Commission’s 7th Framework Programme.

 

The PoC-HCV consortium consists of the coordinator Inserm (Institut Pasteur) (France), Inserm Transfert (France), Qlucore (Sweden),biosurfit (Portugal) and Epistem (United Kingdom)

 

After the identification of useful biomarkers in the management of patients infected by hepatitis C virus (HCV), SPHINX FP7 project, a basis for the migration of assays onto Point-of-care PoC technologies was established.
Genetic and protein biomarkers tested on PoC devices, (Epistem & biosurfit) will be united by new predictive bioinformatics tools and algorithms (Qlucore), allowing for near the patient testing.

 

biosurfit will develop on the spinit® CE-IVD platform, HCV related protein biomarkers quantitation assays and blood quantitation for monitoring anemia and thrombocytopenia in HCV patients.

 

About biosurfit
biosurfit is a Venture Capital backed diagnostics company founded in 2006. The company invented and developed breakthrough technologies that enable fast, precise and affordable blood analysis, aiming for the key parameters that doctors really want. These proprietary technologies are combined in the spinit® instrument, using a user-friendly reader and disposable disk cartridges for specific clinical conditions.
The spinit® instrument uses only one drop of blood to deliver precise results within 10-15 minutes. Initial disposable cartridges to be launched in 2013 include CRP, Blood Count and an Inflammation Panel. It is planned that future tests will include diabetes and cardiac multi-parameter panels.

 

For more information, please contact:

 

Daniel Neves, CMO of biosurfit, tel: +351 218860169